STAAR Surgical Company (STAA) saw its stock price surge 6.35% in intraday trading on Thursday, following the announcement that its Special Meeting of Stockholders regarding the proposed merger with Alcon has been adjourned. This significant uptick reflects investor optimism about the potential merger between the two eye care companies.

The Special Meeting, originally scheduled for October 23, 2025, has been postponed to November 6, 2025, at 8:30 a.m. Pacific Time. STAAR Surgical, known for manufacturing the Implantable Collamer® Lens (ICL), stated that the record date for stockholders eligible to vote remains September 12, 2025. The company emphasized that no other business will be conducted at the adjourned meeting.

This adjournment gives STAAR's shareholders additional time to consider the merger proposal with Alcon, the global leader in eye care. The postponement and the subsequent stock price increase suggest that investors view this development positively, potentially anticipating a favorable outcome for the merger. As the new meeting date approaches, market participants will be closely watching for any further developments in this significant deal within the eye care industry.